Reduced dose, but not reduced risk: rates of inappropriate apixaban dose reduction and stroke and bleeding incidence

27 August 2022 (16:15 - 17:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Josephine Harrington

University of Colorado Boulder, Boulder (United States of America)

7 More presentations in this session

Presentation thumbnail

Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme

Professor R. De Caterina (Pisa, IT)

Abstract Slides

Presentation thumbnail

D-dimer-driven versus standard prophylactic anticoagulation with fondaparinux in critically ill patients with COVID-19 and coagulopathy: an open-label, randomized controlled trial

Doctor L. Adrian (Surabaya, ID)

Abstract Slides

Presentation thumbnail

Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme

Professor R. De Caterina (Pisa, IT)

Abstract Slides

Presentation thumbnail

Performance assessment of unfractionated heparin protocol in pediatric patients supported on extracorporeal membrane oxygenation

Ms E. Shorog (Riyadh, SA)

Abstract Slides

Presentation thumbnail

Protective effect of proton pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis

Doctor H. Ahn (Seoul, KR)

Abstract Slides

Access the full session

Session thumbnail

How to balance efficacy and safety of anticoagulant therapy in clinical practice

The Event

Event poster

ESC Congress 2022

27 August 2022 16:15 CET

You may be interested in

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

Congress Presentation

Antithrombotic therapy in diabetes

Congress Presentation

Contemporary thrombosis management -- state of the state